Eyam Health Graduates from Creative Destruction Lab with Large-Animal Proof of Concept and Expanding Pharma Pipeline

▤ Summary

Eyam Health says it has graduated from Creative Destruction Lab’s Vancouver Biomedical stream after validating its Gemini platform in two large-animal species. The company reports durable single-administration expression approaching six months, expanding pharma partnerships, and its strongest quarter of partnership revenue so far. It positions Gemini as a self-amplifying, LNP-free platform for long-acting biologics, redosable genetic medicines, and next-generation vaccines. Eyam now plans to push lead programs through IND-enabling studies across infectious disease, companion animal health, and oncology.

▦ Linked Companies